Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)
Phase 1, Open-label Study Assessing the Pharmacokinetics, Immunogenicity and Safety/Tolerability of Process 2 Patritumab in Patients With Advanced, Refractory Solid Tumors
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Fáze 1
Kontakty a umístění
Studijní místa
-
-
Florida
-
Tampa, Florida, Spojené státy, 33612
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Spojené státy, 73104
-
-
Texas
-
San Antonio, Texas, Spojené státy, 78229
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Must have a pathologically documented advanced solid tumor that is refractory to standard treatment, for which no standard therapy is available, or for which the subject refuses standard therapy.
- Must have a tumor type that is known to express HER3. These tumors include breast, lung, prostate, ovarian, cervical, endometrial, gastric, pancreatic, bladder, head and neck, liver, colon, and esophageal cancer. Other tumors will be considered based on emerging HER3 expression data.
- Must be competent and able to comprehend, sign, and date an IRB-approved ICF (including HIPAA authorization, if applicable) before performance of any study-specific procedures or tests.
- Must have an ECOG performance status of ≤ 2
Women must be one of the following:
- Postmenopausal (having had no menstrual period for a minimum of 12 months) or surgically sterile, or
- If of childbearing potential, must have been willing to use maximally effective birth control during the period of therapy and use contraception for 6 months following the last investigational drug infusion and must have had a negative urine or serum pregnancy test upon entry into the study.
- Men must be surgically sterile or willing to use a double-barrier contraception method upon enrollment, during the course of the study, and for 6 months following the last investigational drug infusion.
Have hematological function, as follows:6. Men
- Absolute neutrophil count of ≥ 1.5 × 109/L
- Platelet count ≥ 100 × 109/L
- Hemoglobin ≥ 9 g/dL
Have renal function, as follows:
- Calculated creatinine clearance rate (CrCl) ≥ 60 mL/minute using the modified Cockcroft-Gault equation or serum creatinine ≤ 1.5 × ULN.
Have hepatic function, as follows:
- AST ≤ 2.5 × ULN (if liver metastases are present, < 5 × ULN)
- ALT ≤ 2.5 × ULN (if liver metastases are present, < 5 × ULN)
- Alkaline phosphatase ≤ 2.5 × ULN (if bone or liver metastases are present, < 5 × ULN)
- Bilirubin ≤ 1.5 × ULN
- Prothrombin time (PT) or partial thromboplastin time (PTT) ≤ 1.5 × ULN
Exclusion Criteria:
- Have a history of lymphoma, leukemia, or other hematopoietic malignancy.
- Have Have autologous or allogeneic stem cell transplant.
- Have any comorbid medical condition that would increase the risk of toxicity in the opinion of the investigator or sponsor.
- Have untreated or symptomatic brain metastasis.
- Have unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE Version 4.0 Grade 0 or 1, or to levels dictated in the inclusion/exclusion criteria with the exception of alopecia. Subjects with irreversible Grade 2 toxicity may be eligible as per discretion of the investigator and sponsor (e.g., Grade 2 chemotherapy-induced neuropathy).
- Have uncontrolled hypertension (diastolic blood pressure > 100 mmHg or systolic blood pressure > 140 mmHg). It is permissible for the subject to receive treatment with antihypertensive medication to maintain blood pressure within the required parameters.
- Have clinically significant ECG changes that obscure the ability to assess the RR, PR, QT, QT interval corrected for heart rate (QTc), and QRS interval. Subjects with left bundle branch block, atrial fibrillation and use of cardiac pacemaker specifically will be excluded.
- Have ascites or pleural effusion requiring chronic medical intervention.
- Have a history of bleeding diathesis.
- Have had a myocardial infarction within 1 year before enrollment, symptomatic CHF (New York Heart Association > Class II;), unstable angina, or unstable cardiac arrhythmia requiring medication.
- Use of amiodarone within 6 months prior to enrollment.
- Concurrent use of antiarrhythmic medications with the exception of beta blockers for treatment of hypertension.
- Subjects who are receiving drugs that may affect QTc (e.g., quinidine or moxifloxacin).
- QTc interval > 450 msec on the average of the triplicate readings by Friderica's formula on 2 successive screening measurements (second measurement is required if first measurement is > 450 msec).
- Have a LVEF < 50%.
- Have anthracycline exposure greater than 360 mg/m2.
- Have a history of chronic hepatitis or known active infection with hepatitis B virus or hepatitis C virus.
- Personal or family history of long-QT syndrome.
- Have known infection with or a history of testing positive for human immunodeficiency virus (HIV).
- Had treatment with anticancer therapy (6 weeks for nitrosoureas and mitomycin C chemotherapies and 2 weeks for small molecule tyrosine kinase inhibitors), antibody therapy, retinoid therapy, or hormonal therapy within 4 weeks before study Day 1. Prior and concurrent use of hormone replacement therapy or the use of gonadotropin releasing hormone modulators for prostate cancer is permitted.
- Had therapeutic or palliative radiation therapy within 4 weeks before enrollment (in addition, he/she must have had resolution of any significant AEs from radiation therapy at least 2 weeks before enrollment).
- Have concurrent or previous (within 1 week of study Day 1) anticoagulation therapy, except low-dose warfarin (≤ 2 mg/day) or low-dose, low-molecular weight heparin for prophylaxis against central venous catheter thrombosis or deep vein thrombosis.
- Have participated in clinical drug trials within 4 weeks before enrollment.
- Have had major surgery within 4 weeks before enrollment.
- Is currently participating in other investigational procedures.
- Has any disorder that compromised the ability of the subject to give written informed consent and/or comply with study procedures.
- Has known sensitivity to any of the products to be administered during dosing or known allergy to the excipients or investigational drugs.
- Has active infection within 2 weeks before enrollment unless there was a discussion with the sponsor and an agreement was reached that the recent infection would not affect the subject's participation in the study.
- Has previously received an anti-HER3 targeted antibody, including patritumab.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Process 2 patritumab
Process 2 patritumab 18 mg/kg (loading dose) on Day 1 of Cycle 1 followed by Process 2 patritumab 9 mg/kg (maintenance dose) once every 21 days starting on Day 1 of Cycle 2 through Cycle 5.
|
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
AUC (0-21 day) of Patritumab
Časové okno: 5 Cycles, each of which lasts 21 Days
|
AUC (0-21 day) of patritumab obtained after a single infusion of Process 2 patritumab 18 mg/kg (loading dose)
|
5 Cycles, each of which lasts 21 Days
|
|
Cmax of Patritumab
Časové okno: 5 Cycles, each of which lasts 21 Days
|
Cmax of patritumab obtained after a single infusion of Process 2 patritumab 18 mg/kg (loading dose)
|
5 Cycles, each of which lasts 21 Days
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
volume of distribution [Vz]
Časové okno: 5 Cycles, each of which lasts 21 Days
|
To assess the secondary PK parameters volume of distribution [Vz]
|
5 Cycles, each of which lasts 21 Days
|
|
Safety and Tolerability of Process 2 patritumab - (electrocardiograms [ECG)
Časové okno: 5 Cycles, each of which lasts 21 Days
|
To assess the safety and tolerability of Process 2 patritumab (electrocardiograms [ECG)
|
5 Cycles, each of which lasts 21 Days
|
|
Antibody Formation
Časové okno: 5 Cycles, each of which lasts 21 Days
|
To characterize the formation of antibodies to patritumab human antihuman antibodies (HAHA) after infusion of Process 2 patritumab
|
5 Cycles, each of which lasts 21 Days
|
|
Concentration patritumab at 504 hours
Časové okno: 5 Cycles, each of which lasts 21 Days
|
To assess the secondary PK parameter concentration of patritumab at 504h [C504]
|
5 Cycles, each of which lasts 21 Days
|
|
AUC to infinity [AUC0-inf]
Časové okno: 5 Cycles, each of which lasts 21 Days
|
To assess the secondary PK parameters AUC to infinity [AUC0-inf]
|
5 Cycles, each of which lasts 21 Days
|
|
time to Cmax (Tmax)
Časové okno: 5 Cycles, each of which lasts 21 Days
|
To assess the secondary PK parameters time to Cmax (Tmax)
|
5 Cycles, each of which lasts 21 Days
|
|
concentration at the end of infusion (Ceoi)
Časové okno: 5 Cycles, each of which lasts 21 Days
|
To assess the secondary PK parameters concentration at the end of infusion (Ceoi)
|
5 Cycles, each of which lasts 21 Days
|
|
terminal elimination half-life (t 1/2)
Časové okno: 5 Cycles, each of which lasts 21 Days
|
To assess the secondary PK parameters terminal elimination half-life (t 1/2)
|
5 Cycles, each of which lasts 21 Days
|
|
clearance (CL)
Časové okno: 5 Cycles, each of which lasts 21 Days
|
To assess the secondary PK parameters clearance (CL)
|
5 Cycles, each of which lasts 21 Days
|
|
trough concentration (Ctrough)
Časové okno: 5 Cycles, each of which lasts 21 Days
|
To assess the secondary PK parameters trough concentration (Ctrough)
|
5 Cycles, each of which lasts 21 Days
|
|
echocardiograms/multi-gated acquisition [MUGA] scans of Process 2 patritumab
Časové okno: 5 Cycles, each of which lasts 21 Days
|
To assess the safety and tolerability of Process 2 patritumab echocardiograms/multi-gated acquisition [MUGA] scans
|
5 Cycles, each of which lasts 21 Days
|
|
adverse events [AEs] of Process 2 patritumab
Časové okno: 5 Cycles, each of which lasts 21 Days
|
To assess the safety and tolerability of Process 2 patritumab adverse events [AEs] of Process 2 patritumab
|
5 Cycles, each of which lasts 21 Days
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Začátek studia
Primární dokončení (Aktuální)
Primární dokončení
Dokončení studie (Aktuální)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další identifikační čísla studie
Další identifikační čísla studie
- U31287-A-U105
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .